Patent application number | Description | Published |
20080252537 | THROUGH-GLASS ANTENNA SYSTEM - A through-glass antenna system ( | 10-16-2008 |
20080309565 | SIGNAL MEASUREMENT SYSTEM AND METHOD FOR TESTING AN RF COMPONENT - A signal measurement system tests an RF component in an RF test facility, such as an RF anechoic chamber. The system includes a repeater which is connected to an exterior antenna disposed outside the chamber and a transmitting antenna disposed inside the chamber. The repeater receives the RF broadcast signal from the exterior antenna and rebroadcasts it as an RF testing signal inside the chamber. The subject antenna receives the RF testing signal, which is then analyzed with a computer. The repeater may also modify the RF testing signal to produce a wide variety of test situations that mimic those available in a traditional field-test. | 12-18-2008 |
20100194643 | WIDEBAND PATCH ANTENNA WITH HELIX OR THREE DIMENSIONAL FEED - A wideband patch antenna ( | 08-05-2010 |
20130181878 | ANTENNA - A bowtie antenna is presented. The antenna includes a substrate with a metal layer. The bowtie-shaped dipole antenna is formed in the metal layer with two triangle elements and a gap between the two triangle elements. The bowtie-shaped antenna is shaped to receive signals in a lower portion of the UHF band. A pair of transmission lines is formed in the metal extending from the gap. At least one pair of tuning stubs is formed in the metal. The pair of tuning stubs extends from the transmission lines and is tuned to a frequency band that is different than the lower portion of the UHF band. | 07-18-2013 |
20130242852 | PORTABLE WiFi SIGNAL REPEATER - A portable, battery-powered, wireless WiFi signal repeater is presented. It is placed in very close proximity to a WiFi-enabled device and is capable of improving the. communication link between the device and base station. | 09-19-2013 |
Patent application number | Description | Published |
20100168024 | DIRECT UTILIZATION OF PLASMA PROTEINS FOR THE IN VIVO ASSEMBLY OF PROTEIN-DRUG/IMAGING AGENT CONJUGATES, NANOCARRIERS AND COATINGS FOR BIOMATERIALS - The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug. | 07-01-2010 |
20110123446 | DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material. | 05-26-2011 |
20120076832 | SYNTHESIS AND USE OF THERAPEUTIC METAL ION CONTAINING POLYMERIC PARTICLES - Therapeutic particles contain metal ions and are characterized by the use of unique ligand sets capable of making the metal ion complex soluble in biological media to induce selective toxicity in diseased cells. The particles may comprise a polymeric base particle, at least one pharmaceutically active metal ion, including metal ions from more than one metal element, a ligand that is covalently attached to the polymeric base particle and attached to the metal ion via a stimuli-responsive bond, and a cell targeting component. When the metal ion-containing particle enters a pre-defined environment, the ligands binding the metal to the particle are broken, triggering release of the free metal ion while the original ligands remain covalently bound to the particle. | 03-29-2012 |
20150190524 | SYNTHESIS AND USE OF THERAPEUTIC METAL ION CONTAINING POLYMERIC PARTICLES - Therapeutic particles contain metal ions and are characterized by the use of unique ligand sets capable of making the metal ion complex soluble in biological media to induce selective toxicity in diseased cells. The particles may comprise a polymeric base particle, at least one pharmaceutically active metal ion, including metal ions from more than one metal element, a ligand that is covalently attached to the polymeric base particle and attached to the metal ion via a stimuli-responsive bond, and a cell targeting component. When the metal ion-containing particle enters a pre-defined environment, the ligands binding the metal to the particle are broken, triggering release of the free metal ion while the original ligands remain covalently bound to the particle. | 07-09-2015 |
20150299238 | SYNTHESIS AND USE OF PRODRUG COMPLEXES OF COBALT IN POLYMER THERAPEUTICS - Degradable compounds that can be controlled to degrade and can be used for delivery of a cargo component. Cobalt (III) complexes have been exploited as vehicles for molecular complexes. This disclosure describes the use of such complexes as bioconjugation reagents in crosslinking proteins to form particles, PEGylation of proteins, and the synthesis of (bio)polymer-drug conjugates. The Co-based linkages can be designed to respond to internal stimuli, such as changes in pH and reduction potential, or external stimuli, such as applied electromagnetic radiation. Therapeutics are entrapped within these crosslinked particles, covalently attached to the polymer making up the matrix through additional stimuli-responsive linkages, or could comprise the matrix itself. | 10-22-2015 |
20150343085 | Direct Utilization of Plasma Proteins for the In Vivo Assembly of Protein-Drug/Imaging Agent Conjugates, Nanocarriers and Coatings for Biomaterials - The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug. | 12-03-2015 |